Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the LillyMedical.com website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.

  1. Medical Information Right
  2. Diabetes Right
  3. Basaglar (insulin glargine) injection Right
  4. What is the change in HbA1c in type 2 diabetes patients on Basaglar® (insulin glargine)?
Search Basaglar (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Basaglar ® (insulin glargine) injection

100 units/mL

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

What is the change in HbA1c in type 2 diabetes patients on Basaglar® (insulin glargine)?

In patients with type 2 diabetes, treatment with Basaglar provided a mean change in HbA1c of ‑1.3 at 24 weeks that was noninferior to that achieved with comparator insulin glargine 100 units/mL products.

US_cFAQ_BIV017_T2DM_CLINICAL_STUDY_HBA1C
US_cFAQ_BIV017_T2DM_CLINICAL_STUDY_HBA1C
en-US

Basaglar Clinical Study: Type 2 Diabetes

Adult patients with type 2 diabetes participated in a double-blind, active-controlled study to evaluate the glucose lowering effect of once-daily Basaglar® (insulin glargine) 100 units/mL plus oral antihyperglycemic medications (OAMs) compared with that of another insulin glargine 100 units/mL product or a non‑US‑approved insulin glargine 100 units/mL product administered once daily along with OAMs. Patients were

  • insulin naïve (~60%) and had failed to achieve adequate glycemic control on at least 2 OAMs, or
  • already on another insulin glargine 100 units/mL product or a non‑US‑approved insulin glargine 100 units/mL product along with at least 2 OAMs with adequate or inadequate glycemic control (~40%).1

Patient Characteristics

Characteristics of the 759 randomized patients included

  • 78% White
  • 50% male
  • a mean age of approximately 59 years
  • a mean body mass index of approximately 32 kg/m2, and
  • 68% with a glomerular filtration rate >90 mL/min/1.73m2.1

A total of 3 patients randomized to Basaglar did not receive study drug and were not included in efficacy analysis.1

Change in HbA1c

At week 24, treatment with Basaglar provided a mean reduction in glycated hemoglobin (HbA1c) that was noninferior to that achieved with comparator insulin glargine 100 units/mL products (Efficacy Results in Adult Patients With Type 2 Diabetes in a Phase 3 Clinical Study of Basaglar).1

Efficacy Results in Adult Patients With Type 2 Diabetes in a Phase 3 Clinical Study of Basaglar1

HbA1c, %

Basaglar + OAMs
(n=376)a

Comparator Insulin Glargine 100 Units/mL Productsb + OAMs
(n=380)

Baseline, mean

8.35

8.31

Change from baseline, adjusted meanc

-1.3

-1.3

Difference from comparator, adjusted mean (95% CI)c

0.05 (-0.07 to 0.17)

Abbreviations: Basaglar = Basaglar® (insulin glargine) 100 units/mL; HbA1c = glycated hemoglobin; OAMs = oral antihyperglycemic medications.

aA total of 3 patients randomized to the Basaglar treatment group did not receive study drug and were not included in the full analysis set.

bAnother insulin glargine 100 units/mL product and a non-US-approved insulin glargine 100 units/mL product.

cResults were calculated based on the number of patients in the full analysis set using their last observed postbaseline value of HbA1c. Observed HbA1c data at 24 weeks were available from 331 patients (88%) in the Basaglar treatment group and 329 patients (87%) in the comparator insulin glargine 100 units/mL treatment group.

Enclosed Prescribing Information

BASAGLAR® (insulin glargine) injection, for subcutaneous use, Lilly

Reference

1Basaglar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.

Date of Last Review: October 25, 2021

Additional related information:

  • BASAGLAR® (insulin glargine injection) 100 Units/mL: Use in Patients With Type 2 Diabetes Mellitus
Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.17 02/2023 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2023. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    facebook twitter linkedin
    visit www.phactmi.org
    Behringer Ingelheim partner logo and Lilly logo Behringer Ingelheim partner logo and Lilly logo